NGIO is focused on modulating the immune system for the treatment and prevention of disease.
Our patented Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation.
Ii-Key Peptide Vaccines
Our Ii-Key Complete Vaccine turns any target antigenic epitope into an immunotherapeutic vaccine that activates CD4 T-cell long term memory and humoral antibody responses against any tumor antigen where the Ii-Key is linked, hijacking the immune system through antigen presenting cells (APC’s).
NuGenerexIO is working with our partners at EpiVax who have identified such protein fragments or epitopes to generate Ii-Key-SARS 2 peptide vaccines in collaboration with our peptide manufacturing partners. The peptides and Ii-Key are made from naturally occurring amino acids, ensuring an excellent safety profile as well as the ability to rapidly manufacture the commercial scale needed for mass vaccination during a pandemic. With 100 Kg we can create 100 million vaccines.
Immuno-Therapy shows promise in the treatment of multiple cancers. Cancer Immuno-Therapy utilizes a patient’s own immune system rather than toxic chemotherapies to target and eliminate tumors. Over the last decade, antibodies, cellular therapies, and immune checkpoint inhibitors have all become standard of care for the treatment of certain cancers. Our Ii-Key peptide vaccines can work synergistically in combination with these therapies to enhance the immune response and provide long-term protection that may prevent cancer recurrence.
Clinical data from our AE37 studies demonstrate improved outcomes in breast cancer with development programs continuing for breast, bladder and prostate cancers.
With the emergence of the SARS-CoV-2 pandemic, NGIO resumed its robust pandemic vaccine program that previously developed clinical-stage Ii-Key vaccines for Avian influenza (H1N5) and Swine flu (H1N1) before those pandemic threats receded quickly. Using SARS-CoV-2 immune epitopes, we have created a series of Ii-Key-SARS-CoV-2 peptides that are being developed as a Complete Vaccine™, our COVID Ii-Key Complete Vaccine, that specifically modulates the immune system to activate T-Cells and generate targeted neutralizing antibodies, avoiding off-target antibody responses that lead to enhanced non-specific immune responses that result in enhancement of disease and cytokine storm. These immune system activities are determined through our proprietary vaccine development platform that incorporates computational algorithms, convalescent blood screening, and translational research techniques for rapid vaccine development.
Our SARS-CoV2 Vaccine Advantages
- Precise peptide epitope selection
- Validated computer algorithms
- COVID-19 patient blood screen for specificity & safety
- Select Th1 T-Cell Activation
- Antibody screening
- Select peptides that bind neutralizing antibodies
- Eliminate peptides that can produce ADE antibodies (no cytokine storm)
- Scalable synthetic peptide manufacturing
- 100 Kg = 100 Million vaccines
The foundational “Platform Patents” for Ii-Key technology focus on methods of increasing the antigen-specific activation of CD4+ T cells. This cell type is a critical component of the immune system, involved both in the recognition of new pathogenic agents as well as in autoimmune syndromes. The first technology platform (Ii-Key hybrid) relates to a means for increasing the vaccine potency of virtually any protein and while the second (Ii-suppression) relates to generation of an effective cell-based vaccine.
This group of patents relate more specifically to the use of the platform technologies for generating anti-cancer vaccines. We have generated Ii-Key hybrid compounds specifically for patients with breast, prostate, bladder, melanoma and HPV-related cancers.
These patents cover:
- Compositions and Methods Related to Ii Technology
- Ii hybrid peptides used for the enhancement of antigen presentation
- Constructs for the expression of Ii-Key/antigen epitope fusion peptides
- Hybrid Ii-Key/antigen epitope fusion peptides
- Methods for inhibiting Ii expression